Market Place
Sourcing Support
Daxor Validates Blood Volume Analysis Metric At SCCM 2026
26 Mar 2026 //
GLOBENEWSWIRE
Daxor Unveils Portable Blood Volume Analyzer At SCCM 2026
10 Mar 2026 //
GLOBENEWSWIRE
Daxor Corp Joins Iaccess Virtual Alpha Best Ideas Spring
09 Mar 2026 //
GLOBENEWSWIRE
Daxor CEO Feldschuh Shares Progress in Letter to Shareholders
03 Mar 2026 //
GLOBENEWSWIRE
Daxor Reports 45% Revenue Growth, $9.07 NAV for 2025
03 Mar 2026 //
GLOBENEWSWIRE
Daxor Expands Outpatient Reach, Introduces BVA Diagnostic
24 Feb 2026 //
GLOBENEWSWIRE
Daxor Corp Transitions to Exchange Act Reporting
10 Feb 2026 //
GLOBENEWSWIRE
Daxor Corporation Announces $9 Million Registered Direct Offering
23 Jan 2026 //
GLOBENEWSWIRE
Daxor Expands With 3 Facility Adoptions & Next-Gen BVA Analyzer
25 Nov 2025 //
GLOBENEWSWIRE
Daxor CEO Feldschuh To Present At Maxim Growth Summit
21 Oct 2025 //
GLOBENEWSWIRE
Daxor Launches Fda-Cleared Bva Analyzer Amid High Demand And Key
30 Sep 2025 //
GLOBENEWSWIRE
Daxor CEO Michael Feldschuh Provides 1st Half Corporate Update
02 Sep 2025 //
GLOBENEWSWIRE
Daxor Corp`s Replay of Nasdaq Closing Bell Ceremony Now Available
12 Aug 2025 //
GLOBENEWSWIRE
FDA Clears Daxor Corp`s New Rapid, Lightweight Blood Volume
07 Aug 2025 //
GLOBENEWSWIRE
Daxor Study Shows 2.6x Survival in Euvolemic HF Patients
15 Apr 2025 //
GLOBENEWSWIRE
Daxor Corp. Reveals Duke Data, BVA Insights at ACC`s 74th Expo
02 Apr 2025 //
GLOBENEWSWIRE
Daxor Reports NAV At $7.25, 116.5% Revenue Growth In 2023
04 Mar 2025 //
GLOBENEWSWIRE
Daxor CEO Michael Feldschuh Updates Shareholders In New Letter
04 Mar 2025 //
GLOBENEWSWIRE
Daxor Expands Blood Volume Analysis At Major Midwest Center
28 Feb 2025 //
GLOBENEWSWIRE
Daxor Shares Blood Volume Analysis Data From Duke, Yale At THT 2025
19 Feb 2025 //
GLOBENEWSWIRE
Daxor to Exhibit at World`s Largest Critical Care Conference
18 Feb 2025 //
GLOBENEWSWIRE
Daxor Corporation To Exhibit At Heart Failure Society Meeting
19 Sep 2024 //
GLOBENEWSWIRE
Daxor to Present at H.C. Wainwright Global Investment Conference
03 Sep 2024 //
GLOBENEWSWIRE
Daxor CEO Michael Feldschuh Provides Corporate Update in Shareholder Letter
03 Sep 2024 //
GLOBENEWSWIRE
Daxor Launches BVA Program at Mid-South`s Largest Integrated Network
29 Aug 2024 //
GLOBENEWSWIRE
Daxor Awarded $1.9M USAF Contract For Blood Volume Analyzer
06 Aug 2024 //
GLOBENEWSWIRE
Daxor Expands To Three New Facilities For Blood Volume Analysis
05 Aug 2024 //
GLOBENEWSWIRE
Daxor Gets New Contract From Defense Health Agency For Analyzer
24 Jul 2024 //
GLOBENEWSWIRE
Daxor To Showcase BVA-100™ Guided-Care At AAHFN 20th Annual Meeting
18 Jun 2024 //
GLOBENEWSWIRE
Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer
05 Jun 2024 //
GLOBENEWSWIRE
Daxor`s BVA-100 Diagnostic Proves Clinical Benefits in Ambulatory Heart Failure
16 Apr 2024 //
GLOBENEWSWIRE
DAXOR At MedAxiom CardioVascular Conference For BVA Adoption
15 Apr 2024 //
GLOBENEWSWIRE
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
01 Apr 2024 //
GLOBENEWSWIRE
Daxor Corporation Reports Increase in NAV to $7.08 Per Share
18 Mar 2024 //
GLOBENEWSWIRE
Daxor CEO Michael Feldschuh Provides Update in Letter to Shareholders
18 Mar 2024 //
GLOBENEWSWIRE
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference
08 Mar 2024 //
GLOBENEWSWIRE
Daxor to Exhibit at the Technology and Heart Failure Therapeutics Conference
26 Feb 2024 //
GLOBENEWSWIRE
Daxor Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions
12 Feb 2024 //
GLOBENEWSWIRE
Daxor Corporation Closes Q4 2023 with Growth in New Sales
07 Feb 2024 //
GLOBENEWSWIRE
Daxor Corporation to Exhibit at the Society of Nuclear Medicine
29 Jan 2024 //
GLOBENEWSWIRE
Daxor to Exhibit at Society for Critical Care Medicine Critical Care Congress
16 Jan 2024 //
GLOBENEWSWIRE
Daxor Awarded Additional New Patent For Smart Blood Volume Guidance Technology
09 Jan 2024 //
GLOBENEWSWIRE
Daxor Submits Dual 510(k)/CLIA-waiver Application to the FDA
02 Jan 2024 //
GLOBENEWSWIRE
Expert Panelists Advocate Use of Daxor™s Technology
13 Oct 2023 //
GLOBENEWSWIRE
Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use
11 Oct 2023 //
GLOBENEWSWIRE
Daxor Corporation Awarded Support from the NIH Services Program
04 Oct 2023 //
GLOBENEWSWIRE
Daxor to Exhibit at the Heart Failure Society of America Annual Meeting 2023
27 Sep 2023 //
GLOBENEWSWIRE
Daxor To Exhibit at The Medaxiom Cardiovascular Transforum Conference
26 Sep 2023 //
GLOBENEWSWIRE
Daxor Corporation Awarded $305K Grant from the National Institutes of Health
11 Sep 2023 //
GLOBENEWSWIRE
JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®
10 Aug 2023 //
GLOBENEWSWIRE
JACC-HF Study Compares Daxors BVA-100 Volume Metric to CardioMEMS Pressure Metric
12 Jul 2023 //
GLOBENEWSWIRE
Daxor Announces Further Acquisitions of its BVA-100® Blood Volume Diagnostic
11 Jul 2023 //
GLOBENEWSWIRE
Daxor Awarded $1.1 Million Contract from the US Defense Health Agency
05 Jul 2023 //
GLOBENEWSWIRE
Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab
15 Jun 2023 //
GLOBENEWSWIRE
Daxor Corporation to Participate in Maxim Group Virtual Healthcare Conference
12 Jun 2023 //
GLOBENEWSWIRE
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
25 May 2023 //
GLOBENEWSWIRE
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
22 May 2023 //
GLOBENEWSWIRE
Daxor Corporation Announces Proposed Underwritten Public Offering
19 May 2023 //
GLOBENEWSWIRE
Study Shows Utility of Daxor Blood Volume Diagnostic in Heart Failure Outcomes
18 May 2023 //
GLOBENEWSWIRE
New Studies Presented at the 43rd Society for Heart and Lung Transplant
20 Apr 2023 //
GLOBENEWSWIRE
